Alendronate to Prevent Perimenopausal Transition Bone Loss

Trial Profile

Alendronate to Prevent Perimenopausal Transition Bone Loss

Phase of Trial: Phase II

Latest Information Update: 05 Jan 2010

At a glance

  • Drugs Alendronic acid (Primary)
  • Indications Menopause; Osteoporosis
  • Focus Therapeutic Use
  • Most Recent Events

    • 05 Jan 2010 Status changed from recruiting to completed.
    • 05 Jan 2010 Results published in Fertility and Sterility.
    • 05 Jan 2010 Primary endpoint 'Lumbar spine bone mineral density' has been met.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top